<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02819882</url>
  </required_header>
  <id_info>
    <org_study_id>GEICAM 2014-03</org_study_id>
    <nct_id>NCT02819882</nct_id>
  </id_info>
  <brief_title>A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)</brief_title>
  <acronym>REGISTEM</acronym>
  <official_title>A Prospective Registry Study in Patients With Unresectable Locally Advanced or Metastatic Breast Cancer (MBC)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Spanish Breast Cancer Research Group</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Hoffmann-La Roche</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Novartis</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>AstraZeneca</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Pfizer</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Celgene</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Spanish Breast Cancer Research Group</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is a prospective, multicenter non-interventional cohort study designed to develop
      a registry in unresectable locally advanced or metastatic disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The target population for inclusion in this study is breast cancer patients recently
      diagnosed (from January 2016) with unresectable locally advanced or metastatic disease
      (either after a recurrence or as first diagnosis). No treatment regimen will be protocol
      specified. This is an observational study in which clinical decisions concerning the optimum
      management strategy for a particular patient are taken independently of and/or prior to, any
      decision by the physician to invite a patient to participate in the study. The treating
      physician will make all treatment decisions according to his/her regular clinical practice
      independent of this study. Patients enrolled on the study are free to withdraw their informed
      consent for the use and disclosure of health information at any time and when asked, patients
      are not obliged to provide a reason. Patients may request discontinuation from the study at
      any time.

      The date and the reason for withdrawal or discontinuation from the study must be recorded in
      the electronic case report form (eCRF). An attempt will be made to determine the date of
      discontinuation and final status (i. e. withdrawal of consent, loss to follow-up, death) of
      any patient who discontinues from the study. However, the treating clinician is encouraged to
      follow the patient as long as possible, until patient death or through study end. The Sponsor
      has the right to terminate the study at any time. The Sponsor will notify the investigator if
      the study is placed on hold or if the Sponsor decides to discontinue the study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">August 2016</start_date>
  <completion_date type="Anticipated">June 2024</completion_date>
  <primary_completion_date type="Anticipated">June 2024</primary_completion_date>
  <study_type>Observational [Patient Registry]</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <target_duration>5 Years</target_duration>
  <primary_outcome>
    <measure>Number of patients with the different breast cancer subtypes and real distribution of them.</measure>
    <time_frame>8 years</time_frame>
    <description>Number of patients with the different breast cancer subtypes (Luminal A-like, Luminal B-like [HER2 negative], Luminal B-like [HER2 positive], HER2-enriched and Triple Negative) of the unresectable locally advanced or metastatic disease</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Breast cancer and heredofamiliar risk according with the patient and tumor characteristics.</measure>
    <time_frame>8 years</time_frame>
    <description>It will be performed a table with patient and tumor characteristics including only those patients with heredofamiliar risk.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Differences in the development disease in the group of male vs female patients.</measure>
    <time_frame>8 years</time_frame>
    <description>It will be performed an analysis separately for each subtype and by male and female and it will analyse if there are any significative difference between them.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall trends in outcomes by breast cancer subtypes.</measure>
    <time_frame>8 years</time_frame>
    <description>Progression Free Survival (PFS), Overall Survival (OS) and Death will be evaluated between the different cancer subtypes. We will evaluate the prognostic relevance of the intrinsic subtypes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of primary tumor surgery in patient outcomes</measure>
    <time_frame>8 years</time_frame>
    <description>Progression Free Survival (PFS), Overall Survival (OS) and Death will be evaluated considering the type of surgery of the primary tumor.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of timing of primary tumor surgery in patients with metastatic disease as first diagnosis</measure>
    <time_frame>8 years</time_frame>
    <description>Influence of timing of primary tumor surgery in patients with metastatic disease as first diagnosis</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Influence of local therapy (surgery, radiotherapy and radiofrequency) in the outcome of patients with oligometastatic disease</measure>
    <time_frame>8 years</time_frame>
    <description>PFS, OS and Death will be evaluated in with oligometastatic disease and with or without local therapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Prevalence (at entry) and incidence (during the observation period) of pregnancies, abortions and pregnancy outcomes.</measure>
    <time_frame>8 years</time_frame>
    <description>Number of patients pregnant, number of patients pregnant with abortions, and pregnancy outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of participants with specific biomarkers on tumor and blood samples.</measure>
    <time_frame>8 years</time_frame>
    <description>to improve the understanding of metastatic breast cancer by performing analysis on tumor and blood samples.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>IHC/ISH discrepancies between the primary tumor and the metastasis in patients with biopsy of the metastatic lesions.</measure>
    <time_frame>8 years</time_frame>
    <description>It will be performed a comparison between the Immunohistochemistry (IHC)/ In Situ Hybridization (ISH) characteristics of the primary tumor and the metastatic lesion(s).</description>
  </secondary_outcome>
  <number_of_groups>5</number_of_groups>
  <enrollment type="Anticipated">1400</enrollment>
  <condition>Breast Neoplasms</condition>
  <arm_group>
    <arm_group_label>Luminal A-like subtype</arm_group_label>
    <description>Patients that express Estrogen receptor (ER), express Progesterone Receptor (PgR)+ (≥ 20%), don't express HER2 and have Ki-67 'low' (&lt; 14%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luminal B-like (HER2 negative) subtype:</arm_group_label>
    <description>Patients that express ER and are either PgR- or low (&lt; 20%) and/or Ki67 'high' (≥ 14%).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Luminal B-like (HER2 positive) subtype:</arm_group_label>
    <description>Patients that express ER and HER2 irrespective of PgR or Ki67 status.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>HER2-enriched subtype</arm_group_label>
    <description>Patients that express HER2 and don't express ER or PgR.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Triple Negative (TN) subtype</arm_group_label>
    <description>Patients who are negative for the expression of ER, PgR and HER2.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>No intervention</intervention_name>
    <arm_group_label>HER2-enriched subtype</arm_group_label>
    <arm_group_label>Luminal A-like subtype</arm_group_label>
    <arm_group_label>Luminal B-like (HER2 negative) subtype:</arm_group_label>
    <arm_group_label>Luminal B-like (HER2 positive) subtype:</arm_group_label>
    <arm_group_label>Triple Negative (TN) subtype</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood samples Primary and metastatic lesion tissue samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        The target population for inclusion in this study is breast cancer patients recently
        diagnosed (from January 2016) with unresectable locally advanced or metastatic disease
        (either after a recurrence or as first diagnosis).
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Patients (males or females) diagnosed with unresectable locally advanced or MBC
             (either after a recurrence or as first diagnosis) from January 2016.

          2. Able and willing to provide written informed consent.

          3. Age ≥ 18 years.

          4. Availability to medical records access and all data related to the disease management.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Fundación Alcorcón, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital de Donostia, San Sebastián</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Gregorio Marañón, Madrid</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Study Director</last_name>
    <role>Study Director</role>
    <affiliation>Hospital Universitario Reina Sofía,Córdoba</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>MS Study Project Manager</last_name>
    <phone>+34 916892870</phone>
    <email>inicio_ensayos@geicam.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Start-Up Unit Manager</last_name>
    <phone>+34 916892870</phone>
    <email>inicio_ensayos@geicam.org</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hospital General de Elche</name>
      <address>
        <city>Elche</city>
        <state>Alicante</state>
        <zip>03203</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Althaia-Xarxa Assistencial de Manresa</name>
      <address>
        <city>Manresa</city>
        <state>Barcelona</state>
        <zip>08243</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Consorci Sanitari de Terrassa</name>
      <address>
        <city>Terrassa</city>
        <state>Barcelona</state>
        <zip>08227</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Donostia</name>
      <address>
        <city>San Sebastián</city>
        <state>Donostia</state>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Negrín</name>
      <address>
        <city>Las Palmas de Gran Canaria</city>
        <state>Gran Canaria</state>
        <zip>35010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Fundación Alcorcón</name>
      <address>
        <city>Alcorcón</city>
        <state>Madrid</state>
        <zip>28922</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Fuenlabrada</name>
      <address>
        <city>Fuenlabrada</city>
        <state>Madrid</state>
        <zip>28942</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Severo Ochoa</name>
      <address>
        <city>Leganés</city>
        <state>Madrid</state>
        <zip>28911</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Infanta Sofía</name>
      <address>
        <city>San Sebastián de los Reyes</city>
        <state>Madrid</state>
        <zip>28702</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Son Llatzer</name>
      <address>
        <city>Palma de Mallorca</city>
        <state>Mallorca</state>
        <zip>07198</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario de Navarra</name>
      <address>
        <city>Pamplona</city>
        <state>Navarra</state>
        <zip>31008</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Canarias</name>
      <address>
        <city>Santa Cruz de Tenerife</city>
        <state>Tenerife</state>
        <zip>38320</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de Sagunto</name>
      <address>
        <city>Sagunto</city>
        <state>Valencia</state>
        <zip>46520</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Basurto</name>
      <address>
        <city>Bilbao</city>
        <state>Vizcaya</state>
        <zip>48013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario A Coruña</name>
      <address>
        <city>A Coruña</city>
        <zip>15006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Complejo Hospitalario Universitario de Albacete</name>
      <address>
        <city>Albacete</city>
        <zip>02006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Juan de Alicante</name>
      <address>
        <city>Alicante</city>
        <zip>03550</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clinic de Barcelona</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Santa Creu i Sant Pau</name>
      <address>
        <city>Barcelona</city>
        <zip>08041</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>ICO L´Hospitalet</name>
      <address>
        <city>Barcelona</city>
        <zip>08908</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Germans Trias i Pujol</name>
      <address>
        <city>Barcelona</city>
        <zip>08916</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Moisés Broggi_institut Catalá D´Oncologia</name>
      <address>
        <city>Barcelona</city>
        <zip>08970</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital San Pedro de Alcántara</name>
      <address>
        <city>Cáceres</city>
        <zip>10003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Córdoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital de León</name>
      <address>
        <city>León</city>
        <zip>24071</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Lucus Augusti</name>
      <address>
        <city>Lugo</city>
        <zip>27003</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario La Princesa</name>
      <address>
        <city>Madrid</city>
        <zip>28006</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital General Universitario Gregorio Marañón</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario Virgen de la Arrixaca</name>
      <address>
        <city>Murcia</city>
        <zip>30120</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario de Málaga</name>
      <address>
        <city>Málaga</city>
        <zip>29010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Salamanca</name>
      <address>
        <city>Salamanca</city>
        <zip>37007</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Virgen del Rocío</name>
      <address>
        <city>Sevilla</city>
        <zip>41013</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Virgen de la Salud</name>
      <address>
        <city>Toledo</city>
        <zip>45004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>IVO-Instituto Valenciano de Oncología</name>
      <address>
        <city>Valencia</city>
        <zip>46009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Universitario de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46010</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hosital General de Valencia</name>
      <address>
        <city>Valencia</city>
        <zip>46014</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <zip>46017</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico Lozano Blesa</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Hospital Nuestra Señora de Sonsoles</name>
      <address>
        <city>Ávila</city>
        <zip>05004</zip>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>Spain</country>
  </location_countries>
  <link>
    <url>http://www.geicam.org</url>
    <description>Spanish Breast Cancer Research Group (GEICAM) is a Spanish Breast Cancer Research Group</description>
  </link>
  <verification_date>November 2019</verification_date>
  <study_first_submitted>June 20, 2016</study_first_submitted>
  <study_first_submitted_qc>June 27, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 30, 2016</study_first_posted>
  <last_update_submitted>November 29, 2019</last_update_submitted>
  <last_update_submitted_qc>November 29, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">December 3, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Unresectable</keyword>
  <keyword>locally</keyword>
  <keyword>advanced</keyword>
  <keyword>metastatic disease</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

